Sana Biotechnology
Clinical trials sponsored by Sana Biotechnology, explained in plain language.
-
One-Shot cell therapy tested for devastating autoimmune diseases
Disease control OngoingThis is an early safety study testing a single dose of an experimental cell therapy called SC291. It is for adults with severe forms of lupus or a blood vessel disease called ANCA-associated vasculitis that have not improved with at least two prior treatments. The goal is to see …
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
First test of 'Universal' Cancer-Fighting cells in patients
Disease control OngoingThis is a first-in-human study to test the safety and early effects of a new type of cancer treatment called SC291. It is for adults with certain B-cell blood cancers (like non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or not responded to at least two …
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Off-the-Shelf immune cell therapy tested in Tough-to-Treat lymphoma
Disease control OngoingThis is a first-in-human study to test the safety of a new type of 'off-the-shelf' immune cell therapy called SC262. It is for adults with non-Hodgkin's lymphoma whose cancer has come back or stopped responding to treatment, including a prior CAR-T therapy. The main goal is to fi…
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC